Amarin News

Interestingly enough, the two biotech stories that I watch both had patent approval news today.

Amarin had been trading bullish on the heels of their quarterly conference call two weeks ago where they reported a continued increase in Vascepa sales and $2.3 million in recognized Vascepa revenues.

The healthcare sector has been facing significant challenges over the last few years.

Growing Stock Report expands its NASDAQ Gainers Weekly Watch List adding Biogen Idec Inc.

Amarin Co. plc Receives "Outperform" Rating from Leerink Swann Leerink Swann reissued their outperform rating on shares of Amarin Corporation plc in a research report released on Thursday morning, Stock Ratings Network reports.

Last week was quite decent for Amarin Corporation investors, who saw a 6% rally last Friday in reaction to the company's Q1 2013 financial results.

The analysts wrote, "Omthera is developing Epanova, an ultra-pure mixture of the omega-3 fish oils EPA and DHA.

AMRN investors should be aware of a decrease in support from the world's most elite money managers of late.

Welcome to Amarin Corporations Conference Call to discuss its first quarter 2013 financial and operating results.

Nothing has come easy for Amarin . This manufacturer of the ultra-pure fish oil treatment Vascepa has garnered a devoted following of investors who believe that this is not just the next Lovaza acquired in 2007 for $1.7 billion by buying Reliant Pharmaceuticals), but even more.

Senior managers of Amarin Corp. plc, a biotech company with research headquarters in Groton, will discuss the company's first-quarter financial results at 4:30 p.m. Thursday during a conference call.

Amarin longs don't really like me. The same kind of way that Carl Icahn and Bill Ackman "don't really" like each other.

The bull argument for Amarin's Vascepa is simple: it works better than Lovaza, it doesn't have the negative aspects, it doesn't have an atrial fibrillation warning, it is applying for approval to be marketed to a ten times larger patient population, and the combo drug looks to be the best treatment for hyperlipidemia ever created, per the patent ... (more)

Amarin Corporation is one of the most controversial and debated stocks in recent memory.

Amarin Corporation PLC Announces FDA Acceptance of Supplemental New Drug Application for Vascepa for the Treatment of Patients With High Triglycerides -- Amarin Corporation plc , a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health, announced today that the Food and Drug ... (more)

I've been getting tons of messages from Amarin longs who are none too pleased with the articles that I've been penning on Amarin over the last few months.